News
June 2, 2026
UW Medicine News: ADAI Participating in a National Study of a GLP-1 for Alcohol Use Disorder
Associate Professor Mary Hatch, PhD, is leading a site at ADAI for a national clinical trial investigating the use of a GLP-1/GIP drug called brenipatide for the treatment of alcohol use disorder. The study was written up in UW Medicine News today by Brian Donohue. The study, RENEW-ALC, is a 14-month, two-stage trial. In the…
May 29, 2026
LISTEN: KUOW’s “Ask a Doctor” Episode About Ketamine Features ADAI’s Nathan Sackett, MD, MS
Nathan Sackett, MD, MS, Director of the Center for Novel Therapeutics in Addiction Psychiatry at ADAI, was interviewed this week by KUOW for their “Ask a Doctor” series. Dr. Sackett’s work focuses on the intersection between substance use and psychiatric disorders and the therapeutic use of psychedelics for addiction. In the interview, he talks to…
February 2, 2026
Center for Novel Therapeutics in Addiction Psychiatry (NTAP) Joins ADAI!
ADAI is pleased to announce that the UW Center for Novel Therapeutics in Addiction Psychiatry (NTAP) has joined our institute! NTAP’s mission is to “create powerful news ways of treating people struggling with alcohol, opioid, tobacco, and other addictions by combining psychedelic compounds with evidence-based behavioral interventions.” One of their current studies, for example, is…
January 27, 2026
ADAI in the News: People with Psychotic Disorders Link Cannabis Use to Physical Ills (UW Medicine News & KUOW)
People who have psychotic disorders, such as schizophrenia, and who also use cannabis report experiencing a wider range of health problems than previously documented. In a study recently described in a paper in Community Mental Health Journal, ADAI Research Associate Professor Beatriz Carlini, PhD, MPH, and colleagues analyzed survey responses from 4,144 Washington State cannabis…
January 13, 2026
ADAI Assistant Professor Mandy Owens Named to UW Research Impacts Advocates Cohort
Mandy Owens, PhD, an assistant professor with ADAI in the UW Department of Psychiatry & Behavioral Sciences, has been selected to join the inaugural Research Impact Advocates cohort organized by the UW Office of Research. Dr. Owens’ work aims to improve services for people who use alcohol and drugs with a focus on those involved…
December 1, 2025
Congratulations to Dr. Andrew Saxon of the NIDA CTN’s Pacific Northwest Node!
ADAI wants to issue a hearty CONGRATULATIONS to Andrew Saxon, MD, the recipient of the 2025 Outstanding Achievement and Service Award from the American Academy of Addiction Psychiatry (AAAP). [Dr. Saxon is a long-time member of the NIDA Clinical Trials Network’s Pacific Northwest Node, located at ADAI and has been working with many of our staff…
October 17, 2025
New ICD-10-CM Code for Cannabinoid Hyperemesis Syndrome: R11.16
A new ICD-10-CM diagnosis code for Cannabinoid Hyperemesis Syndrome (CHS) went into effect on October 1, 2025. ICD-10-CM codes are used to classify different medical diagnoses, symptoms, and procedures in health records and for billing and claims processing. To date, most health systems have documented CHS using a combination of codes for nausea and vomiting, such…
October 16, 2025
New Videos in the Mental Health Topics for Non-Therapist Professionals Series
The Mental Health Topics for Non-Therapist Professionals series on the LearnAboutTreatment.org website, produced by the ADAI State Opioid Response Training Team, is for providers who work with people with a substance use disorder (SUD) but are not trained as mental health therapists. The goal is to boost knowledge of mental health issues, especially those common…
New Naloxone and Overdose Resources from the WA Department of Health
The WA State Department of Health (DOH) has some new resources out about naloxone and overdose. Issue Brief: The Risks of High-Dose Naloxone Products and Nalmefene for Community Opioid Overdose Response In this issue brief, DOH provides a summary of the current data and their recommendations on opioid overdose reversal medication types and dosages. Key…
September 26, 2025
Carfentanil: What Are We Seeing in Washington State?
From the UW Center for Community-Engaged Drug Education, Epidemiology & Research at the Addictions, Drug & Alcohol Institute The DEA recently reported that more than 50,000 fake pharmaceutical pills were seized by law enforcement in Western Washington. The pills were labeled with “M30” and designed to look like oxycodone. In recent years such pills typically…
Next page
